BioCentury
ARTICLE | Company News

Allos deal

September 19, 2011 7:00 AM UTC

The unsolicited offer, made on Sept. 2, is a 22% premium to Allos' close of $1.64 on that day. The offer is a 3% discount to Allos' close of $2.06 on July 19, before Allos and AMAG announced their merger. Allos' board said the offer "is not reasonably expected to result in an acquisition proposal that is more favorable from a financial point of view" to the AMAG merger. Allos said the suitor was a publicly traded pharmaceutical company with a market cap of less than $500 million (see BioCentury, July 25). ...